180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue
MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.
- MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the Company), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain,announced today that it has selected a lead Synthetic CBD Analogue that is expected to move forward in clinical development for both inflammation and pain.
- As part of a continuing collaboration since 1998 with the pioneer of cannabis chemistry, Raphi Mechoulam (Hebrew University, Jerusalem), Sir Marc Feldmanns (the Companys Co-Executive Chairman and Co-Founder) laboratory, and 180 Life Sciences scientists, identified the non-psychoactive CBD analogue as a lead molecule in the Companys SCA platform.
- Dr. James Woody, 180 Life Sciences Chief Executive Officer, stated, We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Prof Raphael Mechoulam, meets all the criteria desirable to advance to clinical development.
- 180 Life Sciences is leading the research into solving one of the worlds biggest drivers of disease inflammation.